RDHL — RedHill Biopharma Ltd.

Summary of RedHill Biopharma Q1 2022 Earnings Call

1. Key Financial Results and Metrics

• Net Revenues: $18.2 million, down from $22.1 million in Q4 2021, attributed to cyclical trends in Movantik sales.
• Gross Profit: $10.2 million, representing a 56% gross margin.
• Cash Used in Operating Activities: Reduced by over 70% to approximately $4 million from $15 million in Q4 2021.
• Cash Position: Approximately $45 million as of March 31, 2022, prior to a $15 million registered direct offering in May.
• R&D Expenses: Decreased to $3.1 million from $5.9 million in Q4 2021.

2. Strategic Updates and Business Highlights

• Cost Reduction Plan: Aiming for operational cost savings of approximately $50 million over the next 18 months, primarily through a 1/3 reduction in the U.S. commercial workforce and streamlined operational expenditures.
• Commercial Performance: Record quarterly prescription volume for Movantik and Talicia, with Movantik maintaining a 74% market share in the PAMORA class and Talicia becoming the most prescribed H. pylori therapy in the U.S.
• R&D Focus: Continued development of COVID-19 therapeutics (opaganib and RHB-107) and RHB-204 for non-tuberculous mycobacterial disease, with plans to leverage external funding sources for these programs.

3. Forward Guidance and Outlook

• Operational Profitability: Targeting positive cash flow from operations in the second half of 2022.
• Growth Strategy: Focused on organic growth from existing products and potential acquisitions of revenue-generating products to enhance cash generation.
• Market Position: Expecting to maintain strong prescription trends for Movantik and Talicia, supported by improved payer coverage.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The decrease in revenues from Q4 2021 to Q1 2022 raises concerns about the sustainability of sales momentum.
• Workforce Reduction: The reduction of the commercial team could impact sales coverage and overall market presence, although management believes it will not hinder revenue targets.
• Competitive Pressures: New entrants in the H. pylori treatment market could pose challenges to Talicia's market share, despite its strong efficacy profile.

5. Notable Q&A Insights

• Commercial Team Reduction: Management reassured that territories would still be covered through remaining sales representatives and customer engagement specialists.
• Gross to Net Dynamics: The company expects to stabilize gross to net ratios, with improved payer coverage contributing positively.
• Acquisition Discussions: Engaged in non-binding discussions to acquire a GI drug, but no further details were provided.
• COVID-19 Therapeutics Outlook: The evolving nature of the pandemic remains a focus, with ongoing interest in broad antiviral mechanisms to address future waves of infections.

Overall, RedHill Biopharma is navigating a challenging market environment with a focus on cost reduction and operational profitability while maintaining a positive outlook on its commercial products and R&D pipeline.